S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+12.26%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:ORIC

ORIC Pharmaceuticals (ORIC) Competitors

$7.56
-0.25 (-3.20%)
(As of 09/25/2023 ET)
Compare
Today's Range
$7.51
▼
$8.02
50-Day Range
$7.51
▼
$9.28
52-Week Range
$2.36
▼
$9.79
Volume
432,629 shs
Average Volume
299,907 shs
Market Capitalization
$412.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

ORIC vs. OCS, ZYME, ICPT, NRIX, MLYS, JANX, RPTX, TBPH, TRDA, and ME

Should you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Oculis (OCS), Zymeworks (ZYME), Intercept Pharmaceuticals (ICPT), Nurix Therapeutics (NRIX), Mineralys Therapeutics (MLYS), Janux Therapeutics (JANX), Repare Therapeutics (RPTX), Theravance Biopharma (TBPH), Entrada Therapeutics (TRDA), and 23andMe (ME). These companies are all part of the "pharmaceutical preparations" industry.

ORIC Pharmaceuticals vs.

Oculis (NASDAQ:OCS) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends.

ORIC Pharmaceuticals received 28 more outperform votes than Oculis when rated by MarketBeat users. However, 75.00% of users gave Oculis an outperform vote while only 60.66% of users gave ORIC Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
OculisOutperform Votes
9
75.00%
Underperform Votes
3
25.00%
ORIC PharmaceuticalsOutperform Votes
37
60.66%
Underperform Votes
24
39.34%

14.3% of Oculis shares are owned by institutional investors. Comparatively, 91.3% of ORIC Pharmaceuticals shares are owned by institutional investors. 5.3% of ORIC Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ORIC Pharmaceuticals' return on equity of 0.00% beat Oculis' return on equity.

Company Net Margins Return on Equity Return on Assets
OculisN/A N/A N/A
ORIC Pharmaceuticals N/A -40.74%-36.89%

In the previous week, ORIC Pharmaceuticals had 3 more articles in the media than Oculis. MarketBeat recorded 6 mentions for ORIC Pharmaceuticals and 3 mentions for Oculis. ORIC Pharmaceuticals' average media sentiment score of 0.45 beat Oculis' score of 0.31 indicating that Oculis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oculis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ORIC Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oculis currently has a consensus target price of $33.40, suggesting a potential upside of 171.54%. ORIC Pharmaceuticals has a consensus target price of $15.00, suggesting a potential upside of 92.06%. Given ORIC Pharmaceuticals' higher probable upside, equities analysts plainly believe Oculis is more favorable than ORIC Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oculis
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
ORIC Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Oculis has higher revenue and earnings than ORIC Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oculis$960K466.25-$40.55MN/AN/A
ORIC PharmaceuticalsN/AN/A-$89.12M-$2.18-3.58

Summary

Oculis beats ORIC Pharmaceuticals on 7 of the 11 factors compared between the two stocks.


Get ORIC Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORIC vs. The Competition

Export to Excel
MetricORIC PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$425.88M$5.55B$4.31B$6.25B
Dividend YieldN/A2.69%5.83%9.76%
P/E Ratio-3.583.1690.8510.32
Price / SalesN/A153.192,938.4056.58
Price / CashN/A19.0721.3322.66
Price / Book1.394.123.914.84
Net Income-$89.12M$190.86M$120.18M$185.19M
7 Day Performance-6.24%1.40%111.10%4.29%
1 Month Performance-14.08%-2.13%114.32%9.34%
1 Year Performance129.71%7.06%130.51%5.48%

ORIC Pharmaceuticals Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCS
Oculis
2.1356 of 5 stars		$12.50
flat		$33.40
+167.2%		N/A$454.88M$960,000.000.0028News Coverage
Gap Up
ZYME
Zymeworks
2.3613 of 5 stars		$6.90
+1.6%		$12.44
+80.4%		+21.4%$460.55M$447.70M2.46237Positive News
ICPT
Intercept Pharmaceuticals
2.0912 of 5 stars		$11.06
-2.4%		$22.36
+102.2%		-31.2%$462.09M$285.71M1.73341
NRIX
Nurix Therapeutics
1.7543 of 5 stars		$9.34
+4.8%		$27.44
+193.8%		-29.4%$450.19M$38.63M-3.14297Positive News
MLYS
Mineralys Therapeutics
1.8637 of 5 stars		$10.68
-2.4%		$36.00
+237.1%		N/A$446.98MN/A0.0012Positive News
JANX
Janux Therapeutics
1.9447 of 5 stars		$9.64
-4.3%		$28.33
+193.9%		-23.3%$444.40M$8.61M-5.9167Positive News
RPTX
Repare Therapeutics
1.8868 of 5 stars		$12.57
+12.2%		$20.75
+65.1%		+1.6%$471.45M$166.67M-83.80180Analyst Report
News Coverage
Negative News
Gap Up
TBPH
Theravance Biopharma
1.9846 of 5 stars		$8.99
+1.5%		$17.00
+89.1%		-8.8%$474.76M$51.35M0.79359Negative News
TRDA
Entrada Therapeutics
1.7012 of 5 stars		$14.38
+0.4%		$21.50
+49.5%		-4.4%$477.42MN/A-5.57131Analyst Report
ME
23andMe
1.9028 of 5 stars		$1.02
flat		$5.35
+424.5%		-63.9%$481.94M$299.49M-1.42758

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:ORIC) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -